1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25 | On 05/31/2023, Licensing Program Analyst (LPA) Sarena Keosavang arrived at the facility unannounced to follow up on a Case Management- Incident visit conducted on 05/04/2023. LPA met with Executive Director (ED), May Tate, and explained the purpose of the visit.
During the course of investigation, the Department interviewed residents, facility staff, and obtained pertinent documents relevant to the complaint investigation such as, resident’s (R1) physician’s report, medication administration records (MAR), receipt of medications, and medication list.
The Department requested for R1’s physician’s report from the facility for review. The Department obtained an outdated physician’s report that was completed on 12/16/2021. According to physician’s report, R1 is diagnosed with Dementia and is unable to administer own prescription medications.
On 04/27/2023, LPA Keosavang received an email from ED stating the facility was conducting an internal investigation on R1’s medication error. LPA and ED scheduled a telephone call to go over findings of the internal investigation on 04/28/2023. On 04/28/2023, ED stated R1’s MAR indicates that the facility are giving medications to R1, however, if the facility is giving R1 medication they should have refilled those medications by the dates they were supposed to be refilled, but per facility’s nurse, R1’s RP dropped off medications at the facility, but the facility do not have records of when the medications were dropped off and how many medications were dropped off.
The Department received R1’s May 2022 through March 2023 MAR for review. According to R1’s MAR from May 2022 to July 2022, R1’s medications were given to R1. MAR for August of 2023 indicated, staff did not provide R1 Latanoprost on 08/07/2023 and 08/16/2023. On 09/25/2023, MAR indicates staff did not provide R1 Latanoprost. On 10/25/2023, MAR indicates staff did not provide R1 with Dorzolamide, Brimonidine, and Latanoprost. MAR for February of 2023 indicates all 4 medications were provided to R1. MAR for March of 2023 indicates staff did not provide R1 Dorzolamide, Brimonidine, and Rhopressa. MAR does not indicate a reason why medications were not provided to R1.
|